-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Rezalizumab is an interleukin 23 inhibitor and is being studied for the treatment of patients with psoriatic arthritis (PsA)
.
The Phase 2 and Phase 3 trials of KEEPsAKE explored the use of Rezalizumab and placebo to relieve inadequate or intolerance of anti-rheumatic drugs in the past for 2 or less biological therapies (Bio-IR) and/or 1 or more conventional synthetic diseases Efficacy and safety in patients with active PsA (csDMARD-IR)
Recently, Annals of the Rheumatic Diseases, a top journal in the field of rheumatism, published a research article that reported the outcome of the 24th week of PsA patients treated with risalizumab
.
The researchers randomized PsA adults with Bio-IR and/or csDMARD-IR into groups.
During the 24-week double-blind treatment period, the subjects received subcutaneous injections of 150 mg risabizumab at the 0th, 4th and 16th weeks Or placebo treatment
.
The primary endpoint of the study is the proportion of patients with an improvement of ≥20% in the American College of Rheumatology score (ACR20) at week 24.
A total of 444 patients (median age 53 years, range 23-84 years) in the study were randomly assigned to receive risalizumab (n=224) or placebo (n=220) treatment; 206 patients ( 46.
5%) were Bio-IR patients
.
In the 24th week after treatment, compared with placebo, the patients treated with Rezalizumab reached the primary endpoint of ACR20 (51.
Infect
It can be seen that compared with placebo, Resalizumab treatment can significantly improve the outcome of key diseases, and it is well tolerated by PsA patients with Bio-IR and/or csDMARD-IR
.
.
Original source:
Original source:Andrew Östör,et al.
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial in this message
